Dyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data

Dyne Therapeutics Inc. (NASDAQ: DYN) is considered one of the best stocks to buy under $20.

On September 29, Dyne Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation for its investigational therapeutic, DYNE-251.

This designation is specifically for individuals with Duchenne muscular dystrophy (DMD) who have mutations in the DMD gene that are amenable to treatment with DYNE-251.

The Orphan Drug designation is a significant milestone, as it provides certain benefits and incentives to facilitate the development of treatments for rare diseases like DMD.
https://ca.finance.yahoo.com/news/dyne-investigational-dmd-drug-dyne-205457972.html

Leave a Reply

Your email address will not be published. Required fields are marked *